Ymmunobio AG Achieves Major Milestone with YB-800 ADCs in Preclinical Trials Ymmunobio AG's YB-800 ADCs have successfully completed preclinical trials, showcasing significant anti-tumor efficacy, marking a crucial step towards cancer treatment.

Ymmunobio AG Achieves Major Milestone with YB-800 ADCs in Preclinical Trials #Switzerland #ADCs #Ymmunobio #YB-800 #Riehen

Ymmunobio and PSI Collaborate on Innovative Radio-Pharmaceuticals for Cancer Treatment Ymmunobio and the Paul Scherrer Institute join forces with Innosuisse support to advance YB-800, a novel radio-pharmaceutical targeting solid tumors.

Ymmunobio and PSI Collaborate on Innovative Radio-Pharmaceuticals for Cancer Treatment #United_States #cancer_therapy #Princeton #Ymmunobio #YB-800